Cresco Labs has announced non-dilutive debt financing of US$100 million, with an option to increase to US$200 million.
In a "bad" year for the emerging cannabis industry, global cannabis sales rose by 48% in 2019. That's not bad.
The U.S. Food and Drug Administration is claiming that CBD poses significant risks to the human liver. Nonsense.
The largest U.S.-based cannabis company and the largest Canadian cannabis company have both seen their stock make strong moves. Will other cannabis companies follow?
Aphria disappointed slightly on Q2 revenue and its stock is trading lower. Investors may see a buying opportunity here.
Tetra Bio-Pharma takes another step forward in bringing a botanical cannabinoid drug to market for pain relief.
The Food and Drug Administration (FDA) recently announced a policy change that will expedite the marketing of marijuana testing devices if they’re used for certain purposes.
As the U.S. Cannabis Revolution unfolds, over 90% of Americans now want cannabis legalized (at least) for medical purposes. Attention Congress.
We’ve seen our share of ups and downs in the market, but is this the year the gains finally halt and the floor falls out? Short answer: no.